UB Paderborn / Katalog / Suche / in CDI

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

The Lancet (British edition), 2021-01, Vol.397 (10271), p.281-292

2021

Link zum Volltext

Verfügbarkeit prüfen

Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting

Scientific reports, 2021-04, Vol.11 (1), p.8076-8076, Article 8076

2021

Link zum Volltext

Verfügbarkeit prüfen

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Blood, 2012-01, Vol.119 (2), p.476-487

2012

Link zum Volltext

Verfügbarkeit prüfen

Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

Nature communications, 2020-10, Vol.11 (1), p.5173-5173, Article 5173

2020

Link zum Volltext

Verfügbarkeit prüfen

Parental health in fellowship trainees: Fellows’ satisfaction with current policies and interest in innovation

Women's health (London, England), 2020, Vol.16, p.1745506520949417-1745506520949417

2020

Link zum Volltext

Verfügbarkeit prüfen

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Nature communications, 2021-09, Vol.12 (1), p.5574-5574, Article 5574

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

Gynecologic oncology, 2024-07, Vol.186, p.61-68

2024

Link zum Volltext

Verfügbarkeit prüfen

Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients

Journal of palliative medicine, 2018-09, Vol.21 (9), p.1334

2018

Link zum Volltext

Verfügbarkeit prüfen

Oncologic emergencies

Critical care clinics, 2010-01, Vol.26 (1), p.181

2010

Link zum Volltext

Verfügbarkeit prüfen

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Blood, 2016-06, Vol.127 (22), p.2711-2722

2016

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers

Current treatment options in cardiovascular medicine, 2018-02, Vol.20 (2), p.18, Article 18

2018

Link zum Volltext

Verfügbarkeit prüfen

EP114/#688 Evaluating CDK 4/6 inhibitors in combination with endocrine therapy in endometrial cancers: a retrospective study

International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A123-A123

2023

Link zum Volltext

Verfügbarkeit prüfen

755 Evaluating the combination of CDK 4/6 inhibitors and endocrine therapy in endometrial and ovarian cancers: a retrospective study

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A181-A181

2023

Link zum Volltext

Verfügbarkeit prüfen

896 Assessment of cystatin C and creatinine for evaluating renal function in patients receiving PARP inhibitor therapy in ovarian cancer

International journal of gynecological cancer, 2023, Vol.33 (Suppl 3), p.A320-A320

2023

Link zum Volltext

Verfügbarkeit prüfen

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

The New England journal of medicine, 2016-12, Vol.375 (22), p.2154-2164

2016

Link zum Volltext

Verfügbarkeit prüfen

Current and Future Directions for PARP Inhibition

Journal of the advanced practitioner in oncology, 2020-04, Vol.11 (3), p.297-300

2020

Link zum Volltext

Verfügbarkeit prüfen

A multicenter analysis of treatment and outcomes in neuroendocrine carcinoma of the uterine cervix (NCUC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e17518-e17518

2021

Link zum Volltext

Verfügbarkeit prüfen

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3082-3082

2023

Link zum Volltext

Verfügbarkeit prüfen

PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

International journal of gynecological cancer, 2023-11, Vol.33 (Suppl 4), p.A66-A66

2023

Link zum Volltext

Verfügbarkeit prüfen

Symptom identification and management in epithelial ovarian cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5554-5554

2021

Link zum Volltext

Verfügbarkeit prüfen

A phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707) (1308)

Gynecologic oncology, 2023-09, Vol.176, p.S189-S190

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort

Journal of clinical oncology, 2024-01, Vol.42 (3_suppl), p.507-507

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinical Pearls in Oncology 2019

Disease-a-month, 2019-11, Vol.65 (11), p.100863-100863, Article 100863

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

Parental health in fellowship trainees: Fellows’ satisfaction with current policies and interest in innovation

A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients

Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

Oncologic emergencies

4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers

EP114/#688 Evaluating CDK 4/6 inhibitors in combination with endocrine therapy in endometrial cancers: a retrospective study

755 Evaluating the combination of CDK 4/6 inhibitors and endocrine therapy in endometrial and ovarian cancers: a retrospective study

896 Assessment of cystatin C and creatinine for evaluating renal function in patients receiving PARP inhibitor therapy in ovarian cancer

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Current and Future Directions for PARP Inhibition

A multicenter analysis of treatment and outcomes in neuroendocrine carcinoma of the uterine cervix (NCUC)

Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors

PR062/#686 First-in-human phase 1 study of torl-1–23, a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) in patients with ovarian cancer

Symptom identification and management in epithelial ovarian cancer

A phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) nano-immunoconjugate therapy for metastatic gynecological malignancies: MC1371 (NCT02020707) (1308)

Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort

Clinical Pearls in Oncology 2019

Aktive Filter

Suchergebnisse filtern